Project Grant R43GM144973

Award Date 9/1/22
Completion Date 10/31/23
Dollars Obligated $1.1M
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Monmouth Junction, South Brunswick Township, NJ 08852, USA
Similar Awards
This $172,937 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to characterize the physiologic injury and cellular processes that occur during sepsis-induced vasoplegia. The primary objectives are to: Determine the relative severity of injury to vascular smooth muscle cells, endothelial cells, and extracellular matrix in a porcine sepsis model, and examine the role of the...
This $598,228 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at the University of Illinois to investigate the role of endoplasmic reticulum (ER) autophagy in the immune response during sepsis. The key objectives are to: 1) Define how macrophage ER autophagy regulates the NLRP3 inflammasome and lung inflammation in sepsis, 2) Elucidate the molecular mechanisms linking ER...
This $305,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of a clinical decision support system (CDSS) called Sepsis FLO. The CDSS is designed to precisely guide blood volume diagnosis and treatment for sepsis patients. Key activities include: 1) Developing an alpha prototype of the CDSS through user-centered design; 2) Validating three functional...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $455,000.00 to the Children's Research Institute to develop new therapeutic protocols for reducing sepsis mortality in pediatric populations. The key products and services to be delivered include: An AI-guided early identification tool for rapid sepsis detection, 2) Sepsis phenotyping and digital twin patient modeling to...
This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop personalized sepsis therapeutics by integrating high-frequency physiologic data with electronic health record data. The $186,221 award, effective from February 1, 2025 to January 31, 2030, will support three primary research objectives: Augmenting sepsis phenotypes through the inclusion of high-frequency...
This $700,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the clinical validation of Prenosis, Inc.'s Immunix platform for precision medicine endotyping of sepsis patients. The project aims to: 1) validate Immunoscan immunoassays and generate mapping functions to Luminex immunoassays; 2) validate a parsimonious model for point-of-care endotyping; and 3) demonstrate the...
This $1,218,750 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to improve sepsis care through the use of artificial intelligence (AI) and machine learning (ML) clinical decision support systems. The key products and services to be delivered under this 5-year award, which starts on July 15, 2024, include: Addressing critical knowledge gaps at the intersection of AI/ML methods and sepsis...
The National Institute of General Medical Sciences (NIGMS) has awarded a $350,000 Project Grant under the Biomedical Research and Research Training Program (CFDA 93.859) to Medosome Biotec LLC, a for-profit limited liability company based in Bloomington, Indiana. This 1-year project aims to evaluate the safety and therapeutic potential of dichloroacetate (DCA), an investigational drug that inhibits the mitochondrial pyruvate dehydrogenase complex, for the treatment of septic shock. The project...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support the development of a continuous, real-time, automated smart catheter analyzer for early identification of sepsis through urine biomarkers. The $412,250 award to Arizona State University (ASU) will enable the project team, comprising experts in sensors, engineering, computer science, medical research, and medical device manufacturing, to design and develop the...

NOVEL EXTRACORPOREAL THERAPY FOR THE REVERSAL OF SEPTIC SHOCK AND RESTORING HEMODYNAMIC STABILITY - RATIONALE: SEPSIS HAS BEEN CLASSIFIED BY THE WORLD HEALTH ORGANIZATION AS A "GLOBAL HEALTH PRIORITY." IT HAS BEEN ESTIMATED THAT ~50% OF PATIENTS WITH SEPSIS DUE TO GRAM-NEGATIVE BACTERIA WILL DEVELOP SEPTIC SHOCK AND OF THESE, HALF MAY DIE. THERE ARE CURRENTLY NO TREATMENT OPTIONS FOR ATTENUATING THE ELEVATED INFLAMMATORY RESPONSE AND HEMODYNAMIC INSTABILITY THAT IS PRESENT IN THESE PATIENTS. THERAPY IS MAINLY SUPPORTIVE AND LIMITED TO A COMBINATION OF VASOPRESSORS, INTRAVENOUS FLUID, AND ANTIBIOTICS. THE ROLE OF BACTERIAL ENDOTOXIN IN MODULATING THE LEVEL OF HOST-DERIVED INFLAMMATORY MEDIATORS, INCLUDING CYTOKINES, CHEMOKINES, AND COMPLEMENT FACTORS, AND THEIR CONTRIBUTION TO SEPTIC SHOCK IS WIDELY REPORTED IN LITERATURE. WHEN IN EXCESS, THESE MEDIATORS CAN INDUCE ORGAN DYSFUNCTION, MULTIORGAN FAILURE, AND EVEN DEATH. INNOVATION: USE CYTOSORB, A CE MARK APPROVED EXTRACORPOREAL CYTOKINE FILTER, TOGETHER WITH A NOVEL ENDOTOXIN ADSORBER, LPSORB, TO REDUCE BOTH THE TRIGGER AND CAUSATIVE AGENTS OF CYTOKINE STORM AND HEMODYNAMIC INSTABILITY IN SEPTIC SHOCK. HYPOTHESIS: CYTOSORB COMBINED WITH LPSORB ATTENUATES EXCESSIVE LEVELS OF INFLAMMATORY MEDIATORS AND REDUCES LEVELS OF ENDOTOXIN IN SEPTIC PLASMA. SPECIFIC AIMS: 1) CHARACTERIZE THE ENDOTOXIN AND INFLAMMATORY CYTOKINE EXPRESSION PROFILE IN PLASMA FROM SEPTIC PIGS DURING THE DEVELOPMENT OF SEPTIC SHOCK AND ACUTE RESPIRATORY DISTRESS. 2A-C) EVALUATE CYTOKINE AND ENDOTOXIN REMOVAL ABILITY AND THE IMPACT ON PLASMA PH, ELECTROLYTES, INTRINSIC AND EXTRINSIC COAGULATION PATHWAYS AND ALBUMIN LEVELS OF CYTOSORB THERAPY, LPSORB THERAPY, AND CYTOSORB+LPSORB IN PLASMA FROM SEPTIC PIGS IN A BENCHTOP RECIRCULATION SYSTEM. STUDY DESIGN: THE FOCUS OF AIM 1 IS TO CHARACTERIZE CHANGES IN LEVELS OF KEY SEPSIS-ASSOCIATED INFLAMMATORY CYTOKINES AND BACTERIAL ENDOTOXIN IN CIRCULATION DURING THE ONSET OF SEPTIC SHOCK IN THIS HIGHLY CLINICALLY RELEVANT SWINE SEPSIS MODEL IN ORDER TO DRAW CORRELATIONS BETWEEN THE INFLAMMATORY STATUS AND LOSS OF HEMODYNAMIC STABILITY LEADING UP TO MULTIPLE ORGAN FAILURE AND DEATH. PIGS (35KG) WILL BE SUBJECTED TO A '2-HIT' SURGICAL PROCEDURE INVOLVING FECAL CLOT IMPLANTATION IN THE PERITONEAL CAVITY, FOLLOWED BY TRANSIENT CLAMPING OF THE SUPERIOR MESENTERIC ARTERY TO INDUCE SEPTIC SHOCK AND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). BLOOD SAMPLES WILL BE TAKEN BEFORE THE PROCEDURE AND EVERY 6 HOURS AFTER UNTIL THE TERMINAL BLEED AT 36 HOURS. METRICS WILL INCLUDE VITALS (BT, BP, HR, RR), COMPLETE BLOOD COUNTS, BLOOD CHEMISTRIES, AND CYTOKINE AND ENDOTOXIN CONCENTRATIONS. IN AIM 2A-C, CYTOSORB, LPSORB, AND CYTOSORB+LPSORB DEVICES WILL BE EVALUATED IN A SCALED-DOWN BENCHTOP RECIRCULATION SYSTEM FOR CYTOKINE AND ENDOTOXIN REMOVAL CAPACITY AND ANY POTENTIAL IMPACT THE THERAPY MAY HAVE ON PLASMA COAGULATION AND ALBUMIN CONTENT IN SEPTIC PIG PLASMA TAKEN 36 HOURS AFTER THE '2-HIT' PROCEDURE. METRICS WILL INCLUDE CYTOKINE AND ENDOTOXIN CONCENTRATIONS, PT, APTT, UPTT, AND ALBUMIN LEVEL. IMPACT AND TRANSLATION: IF SUCCESSFUL, THIS STUDY WILL CONFIRM THE FEASIBILITY OF IMPLEMENTING CYTOSORB + LPSORB AS A DEFINITIVE TREATMENT FOR SEPTIC SHOCK AND HEMODYNAMIC INSTABILITY. PENDING POSITIVE OUTCOMES IN FUTURE PRECLINICAL AND CLINICAL STUDIES, THIS INNOVATIVE SEPSIS TREATMENT WILL PROVIDE A HIGHLY EFFECTIVE MEANS OF CONTROLLING LIFE-THREATENING HYPERINFLAMMATION DURING THE EARLY STAGES OF SEPTIC SHOCK, WITH THE POTENTIAL TO DRAMATICALLY IMPROVE SURVIVAL.

Posted 8/29/22, 12:00 AM